#reservoir

People whose HIV is locked away in “gene deserts” might be able to interrupt treatment without viral rebound.

The updated report summarizes progress to date, identifies gaps and outlines recommendations for HIV cure research over the next five years.

One new approach protects CD4 cells against HIV entry, while another snips out viral genes in infected cells.

With $600,000 in amfAR HIV grants, research teams explore CAR-T cells, bFAbs and CRISPR/Cas9 gene editing to eradicate the reservoir.

Early treatment is linked to a smaller viral reservoir, but blocking IL-10 and PD-1 might control the virus in those with chronic infection.

Can immunotherapy plus antiretrovirals help the immune system ferret out latent HIV in resting cells?

A grant from AIDS group amfAR helps researchers explore that question and also study COVID-19 “long-haulers” living with HIV.

A refined mapping of HIV’s reservoir could aid in cure research.

The amount of virus hidden in reservoir cells was not tied to inflammation in a small study, but the cells’ production of new RNA was.

Assessing the viral reservoir is traditionally akin to searching for needles in myriad haystacks.

The BEAT-HIV Martin Delaney Collaboratory has issued the first comprehensive set of recommendations for such assessments.

A specific protein on the surface of immune cells taken from the tonsils indicated they were reservoir cells.

Research indicates that there are numerous differences in how HIV behaves in women versus men.

Researchers found that during the earliest phases of infection, the reservoir is quite susceptible to antiretroviral treatment.

The man was treated for lymphoma with a stem cell transplant using immune cells that had an uncommon, naturally occurring resistance to HIV.

In theory, starting antiretrovirals quiets the immune system, leading more immune cells to become part of the inactive reservoir.